Net income came in at 83.49 billion yen (about $924.4 million), hit by the appreciation of the yen against the dollar and the euro, plus higher R&D costs. Sales edged up 0.3% to 494.64 billion yen, driven by Prograf (tacrolimus).
Friday, November 06, 2009
Astellas - Prograf: competition
Astellas Pharma has posted a 8.2% fall in earnings for the first half of the year and cuts its earnings forecast for the full year due to generic competition to its immunosuppressant Prograf.
Net income came in at 83.49 billion yen (about $924.4 million), hit by the appreciation of the yen against the dollar and the euro, plus higher R&D costs. Sales edged up 0.3% to 494.64 billion yen, driven by Prograf (tacrolimus).
Net income came in at 83.49 billion yen (about $924.4 million), hit by the appreciation of the yen against the dollar and the euro, plus higher R&D costs. Sales edged up 0.3% to 494.64 billion yen, driven by Prograf (tacrolimus).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment